Organization to speak at Educase Conference about transforming campus cybersecurity culture TAMPA BAY, Fla., Oct. 27, 2025 /PRNewswire/ -- KnowBe4, the world-renowned cybersecurity platform that...

Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care EAGAN, Minn., Oct. 27, 2025 /PRNewswire/ -- As health care costs continue to rise, Prime...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced a poster presentation at...

Seven distinct studies realized improved symptom control, patient engagement, and satisfaction, in parallel with reductions in healthcare utilization and costs; IBD study earned Presidential...

Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus...

The highly anticipated 2025 IDF World Dairy Summit took place from October 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences...

Ceragon (NASDAQ: CRNT), a leading solutions provider of end-to-end wireless connectivity, announces that management will participate in the following investor conferences in November: Event:...

- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC...

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of...